

Enrico Derenzini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5819741/publications.pdf>

Version: 2024-02-01

96
papers

2,661
citations

185998

28
h-index

197535

49
g-index

97
all docs

97
docs citations

97
times ranked

3699
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	0.8	268
2	Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. <i>Annals of Oncology</i> , 2010, 21, 860-863.	0.6	162
3	Role of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1781-1787.	0.8	160
4	Umbralisib, a Dual PI3K β /CK1 δ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
5	Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 462-466.	0.2	106
6	Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. <i>Cancer Treatment Reviews</i> , 2006, 32, 214-228.	3.4	91
7	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , 2008, 9, 352-358.	5.1	80
8	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. <i>Blood</i> , 2012, 119, 4017-4025.	0.6	79
9	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. <i>Annals of Oncology</i> , 2008, 19, 769-773.	0.6	72
10	Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. <i>Cancers</i> , 2019, 11, 595.	1.7	70
11	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 113, 2496-2503.	2.0	66
12	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
13	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004.	3.2	60
14	Midtreatment ¹⁸ F-fluorodeoxyglucose positron emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 1010-1018.	2.0	60
15	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 6553-6569.	0.8	58
16	The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2011, 1, e46-e46.	2.8	57
17	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
18	Hairy cell leukemia. <i>Cancer</i> , 2010, 116, 4788-4792.	2.0	48

#	ARTICLE	IF	CITATIONS
19	Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2011, 52, 1585-1588.	0.6	48
20	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. <i>Oncotarget</i> , 2017, 8, 14017-14028.	0.8	48
21	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 856-862.	2.0	43
22	The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. <i>Experimental Hematology</i> , 2011, 39, 1007-1017.e1.	0.2	43
23	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. <i>Annals of Oncology</i> , 2010, 21, 1173-1178.	0.6	38
24	Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 775-785.	1.9	36
25	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- κ B Controlled Oxidative Stress Responses. <i>Cancer Research</i> , 2016, 76, 377-389.	0.4	36
26	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 53377-53391.	0.8	34
27	Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 321-325.	0.2	32
28	BET Inhibition-Induced GSK3 β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <i>Cell Reports</i> , 2018, 24, 2155-2166.	2.9	31
29	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. <i>Clinical Colorectal Cancer</i> , 2013, 12, 188-194.	1.0	28
30	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	6.9	28
31	Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. <i>Oncotarget</i> , 2016, 7, 12951-12961.	0.8	28
32	A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 415-420.	0.6	27
33	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013, 31, 183-188.	0.8	27
34	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010, 21, 1877-1883.	0.6	26
35	Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T-Cell Lymphoma. <i>Oncologist</i> , 2014, 19, 746-750.	1.9	25
36	Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. <i>Hematological Oncology</i> , 2013, 31, 223-224.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 258-265.	0.2	21
38	Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. <i>Genome Medicine</i> , 2011, 3, 26.	3.6	20
39	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2013, 54, 2318-2321.	0.6	20
40	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182.	0.8	20
41	Bronchus-Associated Lymphoid Tissue Lymphomas: An Update of a Rare Extranodal Maltoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 566-572.	1.4	19
42	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014, 55, 1471-1478.	0.6	19
43	Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. <i>Journal of Hematology and Oncology</i> , 2018, 11, 75.	6.9	18
44	Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1620-1627.	3.3	15
45	Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. <i>Leukemia and Lymphoma</i> , 2009, 50, 481-484.	0.6	14
46	Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 493-495.	0.2	14
47	Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2013, 163, 681-683.	1.2	14
48	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008, 49, 159-162.	0.6	13
49	High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. <i>BMC Cancer</i> , 2015, 15, 879.	1.1	13
50	Integrated safety analysis of umbralisib, a dual PI3K β /CK1 μ inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	2.5	13
51	Successful combination treatment of clofarabine, cytarabine, and gemtuzumab β ozogamicin in adult refractory B β acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2009, 84, 849-850.	2.0	12
52	Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 258-261.	0.2	12
53	Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed) Tj ETQq1 1 0.784314 rgBT /Overlook 805-807.	0.6	12
54	Chemotherapy after <sc>PD</sc> β 1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. <i>British Journal of Haematology</i> , 2022, 198, 82-92.	1.2	12

#	ARTICLE	IF	CITATIONS
55	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , 2007, 48, 2167-2171.	0.6	11
56	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2022, 36, 197-209.	3.3	11
57	CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. <i>Journal of Neuro-Oncology</i> , 2009, 95, 135-139.	1.4	10
58	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 1015-1021.	0.4	10
59	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 330-334.	1.2	10
60	Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021, 10, 675.	1.8	10
61	Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1695-1701.	2.0	9
62	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index ≤ 1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1824-1829.	0.6	5
63	Collection of Hematopoietic Stem Cells After Previous Exposure to Itrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma. <i>Blood</i> , 2012, 120, 3019-3019.	0.6	5
64	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 24.	2.0	4
65	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade. <i>Blood Advances</i> , 2022, 6, 4634-4644.	2.5	4
66	Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 31 autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 625-628.	1.2	3
67	The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction. <i>Blood</i> , 2010, 116, 2850-2850.	0.6	3
68	In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 1496-1496.	0.6	3
69	The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP. <i>Blood</i> , 2012, 120, 2721-2721.	0.6	3
70	Plasmablastic lymphoma: one or more tumors?. <i>Haematologica</i> , 2021, 106, 2542-2543.	1.7	2
71	Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma. <i>Blood</i> , 2009, 114, 1659-1659.	0.6	2
72	Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques. <i>F1000Research</i> , 2018, 7, 1966.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Slow evolution of liver metastasis from colon cancer. Digestive and Liver Disease, 2005, 37, 628-629.	0.4	1
74	Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies. Blood, 2018, 132, 676-676.	0.6	1
75	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2011, 118, 76-76.	0.6	1
76	Primary Mediastinal Large B-Cell Lymphoma: Investigation On The Role Of Rituximab and PET During Treatment. Blood, 2013, 122, 3046-3046.	0.6	1
77	Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study. Blood, 2016, 128, 3003-3003.	0.6	1
78	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2732-2732.	0.6	1
79	The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma. Blood, 2011, 118, 2731-2731.	0.6	1
80	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. Blood, 2015, 126, 3937-3937.	0.6	1
81	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. Blood, 2015, 126, 2725-2725.	0.6	1
82	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. Leukemia and Lymphoma, 2013, 54, 1791-1793.	0.6	0
83	RALE051: a novel established cell line of sporadic Burkitt lymphoma. Leukemia and Lymphoma, 2018, 59, 1252-1255.	0.6	0
84	Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma. Bone Marrow Transplantation, 2021, 56, 2280-2283.	1.3	0
85	Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.. Blood, 2011, 118, 1604-1604.	0.6	0
86	Abstract 4694: The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma. , 2012, , .		0
87	Abstract 1772: Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL). , 2012, , .		0
88	Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients.. Blood, 2012, 120, 2736-2736.	0.6	0
89	Genomic Instability and Activation Of The DNA Damage Response Pathway Is An Independent Predictor Of Poor Prognosis, Is Associated With MYC Expression and Is a Promising Target For Therapy In Diffuse Large B Cell Lymphoma. Blood, 2013, 122, 3015-3015.	0.6	0
90	Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. Blood, 2013, 122, 5543-5543.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Abstract LB-105: In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. , 2014, , .		0
92	Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients. Blood, 2014, 124, 5458-5458.	0.6	0
93	The Treatment of Primary Mediastinal Large B-Cell Lymphoma: A Two Decades Monocentric Experience on 98 Patients. Blood, 2014, 124, 4440-4440.	0.6	0
94	Efficacy and Safety of Biosimilar Epoetin Alpha in Patients with Chronic Lymphoproliferative Syndromes and Chemotherapy-Induced Anemia: An Observational, Retrospective, Monocentric Analysis. Blood, 2014, 124, 5478-5478.	0.6	0
95	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2478-2478.	0.6	0
96	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	0.6	0